Rationale, design, and baseline characteristics of the Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection: EPIC-HIV Randomized Clinical Trial

By afschroeder • March 3, 2026

Durstenfeld MS, Levkova-Clark M, Ms DL, Schaffer V, Abohashem S, Ma Y, Kawai K, Lu MT, Sereti I, Deeks SG, Tawakol A, Hsue PY. Rationale, design, and baseline characteristics of the Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection: EPIC-HIV Randomized Clinical Trial. Am Heart J. 2026 Feb 28:107400. doi: 10.1016/j.ahj.2026.107400. Epub ahead of print. PMID: 41771366.

Tags: arterial inflammation, Cardiology/Epi, Cholesterol, Clinical Trial, Coronary Atherosclerosis, HIV, PCSK9, Publications

Target Versus Below-Target Dose ACE Inhibitors in U.S. Veterans with HFpEF: Differential Outcomes by CKD Status

Lu F, Ahmed AA, Zhang S, Raman VK, Patel SS, Vargas JD, Fonarow GC, Heidenreich PA, Cleland JGF, Anker SD, Böhm M, Metra M, Zile[...]

Heart Failure with Preserved Ejection Fraction in Women: Sex-Specific Insights Across the Continuum from Diagnosis to Outcomes

Andrade-Bucknor S, Barforoshi S, Le DE, Lyubarova R, Chung J. Heart Failure with Preserved Ejection Fraction in Women: Sex-Specific Insights Across the Continuum from Diagnosis[...]

Transthyretin Cardiac Amyloidosis in an Older Athlete

O'Brien D, Reiss RA. Transthyretin Cardiac Amyloidosis in an Older Athlete. Cureus. 2026 Jun 29;18(6):e111747. doi: 10.7759/cureus.111747. PMID: 42534173; PMCID: PMC13419844.